David Milroy

Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered the early detection and identification of cancer employing infrared spectroscopy of circulating pan-omic biomarkers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. Dxcover is based in Scotland, United Kingdom and is establishing operations in the USA.

Concinnity is developing an AI-driven RNA design platform to build gene control systems for gene and cell therapies. Our RNA-based control systems will form part of the gene therapy cassette and enable precise control of therapeutic activity. Such control systems have huge potential to enhance both patient safety and therapeutic efficacy, for example by allowing a gene therapy to dynamically adjust its activity in response to patient disease state, recognise tissue type, or by allowing clinical control of the therapy after administration.

Nami Surgical stands at the forefront of healthcare innovation, pioneering in the creation of miniaturised ultrasonic surgical devices optimised for use in robotic systems and minimally invasive surgeries. Our breakthrough solutions are designed to elevate patient care and empower surgeons with intuitive, high-performance maneuverable tools for complex surgical tasks.

Carcinotech provides comprehensive solid tumor research services to advance drug development and enhance personalized therapy decisions. At the heart of its offerings is the proprietary Carcino3D™ bioprinting technology, which creates assay-ready, 3D tumors derived from patient biopsies. This innovative, translational approach delivers a predictive in vitro model, generating critical insights into therapeutic efficacy, and treatment optimization.

We enable financial services firms to meet their most complex regulatory requirements through specialist technology and expert-led advisory services.

Symphonics context-aware and fine-grained authorization software solution allows organizations to manage access to data and services in the API-driven and inter-connected digital economy. The solution provides centralized visibility and control over the policies that apply to an enterprises entire digital landscape through a powerful policy management interface. Access management is simpler and more agile and our solution supports rapidly emerging needs for sharing data both inside and outside an organisation whilst maintaining compliance with internal policies and external regulations. Symphonics solution is deployed in the banking, health, pharmaceutical and FMCG sectors, with clients in Europe, Australasia and the US. Through its network of partners, Symphonic has the capability to service client needs worldwide.

Bsolve Dental manufactures thin dissolvable and absorbable thin films which carry and release active ingredients. Products include dissolving Teeth Whitening strips, Melatonin, caffeine, other OTC products and pharmaceutical products. We are Europe’s only fully integrated producer of such films; ‘Fully integrated’ means we can take innovative concepts right through from initial research to development, manufacture, packaging and final delivery. Combined with our flexible approach, this makes us unique in our ability to partner clients from the earliest stages of their projects through to market, thus enabling them to launch products quickly and cost effectively. With our highly experienced R&D team on-site, concepts can be prototyped, tested and scaled up quickly to respond exactly to customer specifications. Soluble strip technology is a relatively new development which allows small quantities of active ingredients to be delivered in a user-friendly format. Adapting existing products such as oral sprays, liquids or tablets, or exploiting entirely new opportunities, Bsolve Dental works closely with clients to create the most effective thin film product and process solutions.

Spaceright Europe Limited have been manufacturing education and office products for over 100 years. We are the manufacturer and supplier of numerous trusted brands, and our products can be be found in nurseries, schools and offices across the UK, Europe and further afield. We have established ourselves as market leaders in presentation products and in recent years, we have completed two acquisitions in curriculum and early years categories (Edtech and Millhouse), which strengthens our product portfolio and manufacturing capabilities. Based in the UK, we have two manufacturing sites in Glasgow and Lincoln. We are committed to investing in new product development and technological efficiencies, to enable us to successfully deliver cutting edge solutions for our customers.

Calnex Solutions designs, produces and markets test instrumentation and solutions for network synchronization and network emulation, enabling our customers to validate the performance of the critical infrastructure associated with the telecoms networks. We have established a position at the forefront of the test and measurement industry, providing our equipment to the worlds telecoms network operators, network providers, systems suppliers, laboratories and network infrastructure. To date, we have secured and delivered orders from over 600 customer sites in 68 countries across the world. Founded in 2006, we are headquartered in Linlithgow, Scotland, with additional locations in Belfast, Northern Ireland and California in the US, supported by sales teams in China and India. We have a global network of partners, providing a worldwide distribution capability. In 2015, Calnex was awarded the Queens Award for Enterprise for International Trade, recognising our international reputation for innovative products and global sales achievements and in 2020 we were named “Exporter of the Year” by the China-Britain Business Council at the China-Scotland Business Awards. Calnex Solutions is an ISO9001 certified company.

Approov delivers cloud-native mobile app security trusted by global leaders in eCommerce, finance, healthcare, gaming, and the connected vehicle ecosystem. Our patented mobile runtime integrity and API protection technology ensures that only genuine, untampered mobile apps can access your backend services—unified seamlessly across iOS and Android. As mobile apps have become the front door to digital business, they are increasingly targeted by automated attacks, reverse engineering, and API abuse. Approov brings a cloud-native Zero Trust approach to mobile app security, continuously verifying the integrity of each app instance and device before granting API access. We secure the entire mobile-to-cloud channel—protecting your APIs from scripts, bots, repackaged apps, and emulators in real time. Our platform provides: Dynamic, runtime attestation with zero false positives Just-in-time delivery of API secrets, certificates, and tokens Built-in Runtime Application Self-Protection (RASP) for enhanced on-device defense End-to-end telemetry and visibility from app to API By embedding lightweight SDKs in your apps and using a cloud-native attestation service, Approov gives security, DevOps, and compliance teams centralized control over a distributed mobile threat surface—without slowing innovation. Founded as CriticalBlue in Edinburgh, Scotland, with U.S. operations in Palo Alto, California, Approov launched its mobile API protection platform in 2017 after years of R&D in binary analysis, runtime integrity, and secure system performance. Our roots in deep systems engineering have evolved into a platform that powers security for millions of users globally. Approov is redefining mobile app security for the cloud-native era. 🔗 Learn more at www.approov.io

Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered the early detection and identification of cancer employing infrared spectroscopy of circulating pan-omic biomarkers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. Dxcover is based in Scotland, United Kingdom and is establishing operations in the USA.

Concinnity is developing an AI-driven RNA design platform to build gene control systems for gene and cell therapies. Our RNA-based control systems will form part of the gene therapy cassette and enable precise control of therapeutic activity. Such control systems have huge potential to enhance both patient safety and therapeutic efficacy, for example by allowing a gene therapy to dynamically adjust its activity in response to patient disease state, recognise tissue type, or by allowing clinical control of the therapy after administration.

Nami Surgical stands at the forefront of healthcare innovation, pioneering in the creation of miniaturised ultrasonic surgical devices optimised for use in robotic systems and minimally invasive surgeries. Our breakthrough solutions are designed to elevate patient care and empower surgeons with intuitive, high-performance maneuverable tools for complex surgical tasks.

CALCIVIS is an innovative UK dental biologic and device manufacturer focused on revolutionising treatment of tooth decay and enabling preventive dentistry. Headquartered in Edinburgh, Scotland, CALCIVIS brings world-class development and business management expertise to a sector eager to reduce reliance on costly, complex and painful surgical interventions. CALCIVIS is focused on revolutionising the management of dental demineralization by providing what leading clinicians consider to be the “Holy Grail” of cariology (tooth decay): real-time chair side assessment of the caries disease process. Information about activity of enamel demineralization has not been available previously and enables the preventive dentistry approach. By supporting early decision making and improving patient communication, compliance with oral health advice increases and consent for prescribed treatment improves leading to enhanced clinical and professional outcomes.